Alivus Life Sciences Ltd vs Dishman Carbogen Amcis Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 12 Jun 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Dishman Carbogen Amcis Ltd changed from 161 on March 2022 to 1036 on March 2025 . This represents a CAGR of 59.28% over 4 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 1708 crore on March 2021 to ₹ 3411 crore on March 2025 . This represents a CAGR of 14.83% over 5 years The revenue of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Dishman Carbogen Amcis Ltd for the Mar '26 is ₹ 867.82 crore as compare to the Dec '25 revenue of ₹ 726.46 crore. This represent the growth of 19.46% The ebitda of Alivus Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Dishman Carbogen Amcis Ltd for the Mar '26 is ₹ 178.22 crore as compare to the Dec '25 ebitda of ₹ 119.77 crore. This represent the growth of 48.8% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Dishman Carbogen Amcis Ltd changed from ₹ -77.57 crore to ₹ 21.74 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 yearsThe Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited was formerly incorporated as 'Carbogen Amcis (India) Limited' on July 17, 2007.
The Company name later on, was changed to 'Dishman Carbogen Amcis Limited' on 27 March 2017.
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants.
It works manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.
The name of Carbogen Amcis (India) Ltd.

FAQs for the comparison of Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Dishman Carbogen Amcis Ltd?

Market cap of Alivus Life Sciences Ltd is 12,850 Cr while Market cap of Dishman Carbogen Amcis Ltd is 2,891 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd?

The stock performance of Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd?

As of June 15, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1046.95. On the other hand, Dishman Carbogen Amcis Ltd stock price is INR ₹184.45.

How do dividend payouts of Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Dishman Carbogen Amcis Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.